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ABSTRACT 
Background: Several studies have been made about pidotimod (PDT) and 
encouraging results have been collected. PDT is a synthetic dipeptide molecule 
that seems to have immunomodulatory activity on both innate and adaptive 
responses. Until now, the effects of PDT on the immune system have only been 
studied in vivo after long-term administration to evaluate whether its 
immunomodulatory activity might prevent the development of infections. This study 
was planned to evaluate the immunomodulatory activity of PDT administered 
together with standard antibiotic therapy in patients hospitalized for community-
acquired pneumonia (CAP). 
Methods: A total of 36 patients, including 20 children and 16 adults hospitalized for 
community-acquired pneumonia (CAP) were randomized at a 1:1 ratio to receive 
either standard antibiotics plus pidotimod (PDT) or standard antibiotics alone to 
evaluate the immunomodulatory activity of PDT. In Children blood samples for the 
evaluation of immunological parameters were draw at the time of recruitment 
before therapy administration (T0), at 3 and 5 days after the initiation of therapy (T3 
and T5), and 7 days after the therapy ended (T21). While adults blood samples 
were taken at T0 before therapy administration, T1, T3 and T5 (respectively after 1, 
3 and 5 days from the beginning of the therapy). Isolated PBMC were stimulated 
for 3 hours for gene expression analysis, and 18 hours for cytometric analysis. 
Results: Following pneumococcal polysaccharide stimulation, in both groups, the 
percentage of dendritic cells (DCs) expressing activation and costimulatory 
molecules was significantly higher in patients receiving PDT plus antibiotics than in 
the controls. A significant increase in tumor necrosis factor-α and/or interleukin-12 
secretion and expression of toll like receptor 2 was observed in PDT-treated 
children compared with controls. In adults results shown an increase of both TLR2 
and TLR4, whereas no consistent effects of pidotimod on IL12 producing immune 
cells could be detected, TNFα producing monocytes and DCs were robustly 
reduced in pidotimod patients. In the PDT-treated groups, mRNA expression of 
antimicrobial peptides and genes involved in the inflammatory response were also 
augmented in comparison with the controls. 
Conclusions: These results confirm that supplementation of antibiotic therapy with 
Pidotimod in patients with CAP results in a potentially beneficial modulation of 
innate immunity.        
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SOMMARIO 
Introduzione: Il pidotimod (PDT) è una molecola dipeptidica di sintesi ad azione 
immunomodulante. Tale composto è studiato già da diversi anni con incoraggianti 
risultati a carico sia del sistema immunitario innato che adattativo. Studi in vitro ed 
in vivo ne hanno già dimostrato i benefici effetti nel trattamento di molte patologie. 
Col nostro studio abbiamo voluto porre l’accento sugli effetti del PDT associato alla 
terapia antibiotica standard in pazienti ospedalizzati per polmonite contratta in 
comunità (CAP). 
Metodi: 36 pazienti ospedalizzati per CAP, di cui 20 bambini e 16 adulti, sono stati 
arruolati nello studio secondo specifici criteri di inclusione. I pazienti sono stati 
suddivisi in due gruppi di trattamento, al primo è stato somministrato PDT 
associato alla terapia antibiotica standard, al secondo la sola terapia antibiotica. I 
campioni di sangue sono stati prelevati a diverse tempistiche, i bambini sono stati 
prelevati al momento dell’arruolamento (T0), a 3 e 5 giorni dall’ inizio della terapia 
(T3 e T5), e a 7 giorni dalla fine della somministrazione farmacologica (T21), Gli 
adulti sono stati invece prelevati al momento dell’arruolamento (T0), e 
rispettivamente a 1, 3, e 5 giorni dall’inizio della terapia (T1, T3, T5). Le PBMC 
sono state isolate da sangue periferico e stimolate in presenza di pneumococco. 
Dopo 3 ore di stimolazione una parte delle cellule è stata utilizzata per l’estrazione 
dell’RNA per la valutazione dell’espressione di specifici geni coinvolti nella risposta 
antibatterica; mentre dopo 18 ore di stimolazione le restanti cellule sono state 
marcate per le analisi citofluorimetriche. 
Risultati: I risultati ottenuti nei bambini hanno evidenziato un’azione del PDT su 
cellule denritiche, dove modula l’espressione di marker di attivazione e molecole 
costimolatorie quali HLA DRII, CD80 e CD86; e monociti, sui quali incrementa 
l’espressione del TLR2. Inoltre il gruppo trattato con PDT manifesta anche 
un’incremento nella secrezione di citochine proinfiammatorie TNFα e IL-12. Negli 
adulti è stato anche osservato un aumento nell’ espressione del TLR4 a livello dei 
monociti, mentre nessuna differenza è stata osservata nella secrezione delle 
citochine proinfiammatorie. In aggiunta, in entrambi i gruppi si è osservata una 
modulazione nell’ espressione di geni coinvolti nella risposta infiammatoria e 
antimicrobica. 
Conclusioni: Questi risultati confermano gli effetti immunomodulanti del PDT già 
descritti in letteratura, nonché i benefici della molecola associata alla terapia 
antibiotica standard nei pazienti affetti da CAP, grazie alla sua azione a livello 
dell’immunità innata.  
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LIST OF ABBREVIATION 
 
ACIP: Advisory Committee on Immunization Practices  
AECs: Airway epithelial cells  
AMP: Antimicrobial peptide  
APCs: Antigen presenting cells  
ARTIs: Acute Respiratory Tract Infections 
BCG-PSN: Bacillus Calmette-Guerin polysaccharide nucleic acid  
B.I.D.: Bis in Day (twice a day) 
BMDMs: Bone marrow-derived macrophages 
CAP: Community-Acquired Pneumonia  
CLRs: C-type lectin receptors 
COPD: Chronic obstructive pulmonary diseases  
CTLs: Cytotoxic T lymphocytes  
CY: Cyclophosphamide  
CRP: C-reactive protein 
CWPS: Pneumococcal cell wall  
D53: Ribomunyl  
DCs: Dendritic cells  
DS: Down syndrome  
EDTA: Ethylenediaminetetraacetic acid 
ERK1/2: Extracellular-signal-regulated kinase  
GIT: Gastrointestinal tract  
GM-CSF: Granulocyte-monocyte secretion factor   
HBEC: Human bronchial epithelial cells  
IL-1: Interleukine-1  
IL-6: Interleukin 6 
IL-8: Interleukin 8 
IL-10: Interleukin 10 
ILCs: Innate lymphoid cells 
INF: Interferon 
LPS: Lipopolysaccharide  
LW 50020: Luivac  
IECs: Intestinal epithelial cells  
MENK: Methionine encephalin 
MRSA: Methicillin-Resistant Staphylococcus Aureus  
NF-kB: Nuclear factor-kappa B 
NK: Natural killer cells 
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NLRs: (NOD)-like receptors  
NTHi: Non typeable H. influenza  
OM: Otitis media  
OM-85 BV: Broncho Vaxom  
PBS: Phosphate buffered saline 
PCT:  Procalcitonin 
PPV23: Pneumococcal polysaccharide vaccine  
PVC: Pneumococcal conjugate vaccine  
PRRs: Pattern-recognition receptor 
PMBL: Polyvalent mechanical bacterial lysate  
PDT: Pidotimod 
PSI: Pneumonia Severity Index  
RLRs: RIG-I-like receptors  
RT: Reverse transcriptase 
RU 41740: Biostim  
TH1: T helper type 1  
TH2: T helper type 2 
TH17: T helper type 17 
TLRs: Toll-like receptors  
TGFβ: Transforming growth factor-β  
TNF: Tumor Necrosis Factor  
TRM: Tissue-resident memory T cells 
VBNC: Viable-but-non-culturable state 
WBC: White blood cell 
WHO: World Health Organization  
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1. RESPIRATORY INFECTIONS 
 
Respiratory infections are the most common infectious diseases. They 
have been known and studied for many years, but the high incidence of 
hospitalization and the spread of resistant microorganisms make it 
necessary to find new preventive and therapeutic approaches. Furthermore 
respiratory infections are associated with high morbidity and mortality, 
especially in immunocompromised patients [1]. 
Acute Respiratory Tract Infections (ARTIs) are the most common diseases 
at the pediatric age [2]; indeed children are more susceptible to developing 
respiratory infections due to the vulnerability of their immune system [3]. In 
fact, it is estimated to be the cause of death in 19% of cases in children 
under five years. Moreover, ARTIs are the main cause of morbidity in 
industrialized countries. Data collected from the World Health Organization 
(WHO) showed that ARTIs are responsible for 20% of medical 
consultations, 30% of days lost from work, and 75% of antibiotic 
prescriptions [4].  
Among the risk factors described for childhood, there are: contact with elder 
siblings, smoking at home, overcrowding, daycare centres and lack of 
breast feeding. However, even in a healthy population, in the absence of 
any risk factor, there is a subgroup of people with a higher incidence of 
ARTIs [4].   
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1.1 Community Acquired Pneumonia (CAP) 
Community-Acquired Pneumonia (CAP) is a leading respiratory infection. 
Currently it represents one of the most common infections in children 
worldwide. 
Risk factors are represented by a history of upper respiratory tract 
infections, poor socioeconomic conditions, passive smoke, asthma or other 
comorbidities and poor nutrition [5]. 90% of death due to pneumoniae 
occurs in adults over 65 years old. Other risk factors in adults are: 
alcoholism, immunosuppressive conditions, cardiovascular disease, 
cerebrovascular disease, chronic liver or renal disease, diabetes mellitus 
and dementia [6]. 
Children require hospitalization, and in some cases adults too. 2-14% of the 
hospitalized patients will die, and 12% will go in to relapse within 30 days of 
hospital discharge. Surprisingly, non-recurrent cases still are associated 
with a reduced survival rate. The reasons are unclear, probably it is due to 
other predisposing factors. CAP also has an important economic impact on 
society, both directly and indirectly [7]. 
 
1.2 Etiology 
CAP is generally caused by intracellular bacteria, which varies from country 
to country. Intracellular bacteria associated with pneumonia are: Legionella 
pneumophila, Mycoplasma pneumonia, Chlamydophila pneumoniae, 
Chlamydophila psitiacci, and Coxiella burnetii. Generally, these pathogens 
are associated with extrapulmonary manifestations, but clinical features are 
characterized by classical bacterial agents such us Streptococcus 
pneumonia, and Haemophilus influenziae [8,9]. 
Staphylococcus aureus and Klebsiella pneumonia are associated with a 
smaller percentage of CAP, in particular, K pneumoniae has been 
associated with a higher incidence of mortality than S. Pneumonia [10].  
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1.2.1 Legionella pneumophila 
Legionella pneumophila is a Gram-negative intracellular pathogen that 
causes atypical pneumonia, and presents some similar clinical and 
radiographic symptoms of S. pneumonia [11]. Several serotypes have been 
identified; the most common in Europe is serotype 1, which is responsible  
for 90% of pneumoniae cases [8]. 
Incubation period spans between 2 and 14 days. Then, the disease 
manifests itself with headache, myalgia, asthenia and anorexia. 
The infection occurs through inhalation of a contaminated aerosol from 
lungs of infected people. L. pneumophila enters in alveolar macrophages 
where it first replicates. The presence of chronic lung disease increases 
illness susceptibility [11]. In nature, L. pneumophila lives in a water 
environment in low percentage, while it increases in human-made aquatic 
habitat, at 25-55°C. At these temperatures, Legionella is able to replicate in 
some protozoa, amoebae and slime moulds, thanks to the presence of 
biofilms. After an extended stay in water, Legionella enters a viable-but-
non-culturable state (VBNC), and in this form it can survive for a long time 
and infect the host cell [11]. 
 
1.2.2 Mycoplasma pneumonia 
Mycoplasma pneumoniae is one of the most common causes of atypical 
pneumonia, particularly prevalent in children and young adults, but it can 
produce also ear infections such as otitis media [12]. It may cause up to 
35% of hospitalizations of CAP cases [13].  
M. pneumoniae is an intracellular pathogen without cell wall structure, 
which confers resistance to β-lactam antibiotics [8]. It is a very small 
pathogen, so infection can occur between people in close contact via 
droplets, as a result of coughing. 
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M. pneumonia can infect both upper and lower respiratory tracts, and in 
some cases the infection can last very long time  [13].  The incubation 
varies from 1 to 3 weeks, and furthermore, the spread of the pathogen is 
possible a long time after infection, prolonging the epidemic [8]. 
 
1.2.3 Chlamydophila pneumonia 
Chlamydophila pneumonia is a widespread intracellular pathogen of 
respiratory tract infection. It is estimated that over a lifetime approximately 
everyone has entered in contact with the bacterium. 70% of respiratory 
infections due to C. pneumonia are asymptomatic, and 2,2-8% of CAP 
cases are caused by C. pneumonia [14]. Further, this kind of infection 
worsens the symptoms in chronic diseases, such as asthma and chronic 
obstructive pulmonary diseases (COPD) [9,14]. The incubation lasts about 
3 weeks, and the infection occurs through inhalation of aerosol 
contaminated with bacteria. C. pneumonia is able to survive for a long time 
in quiescent  phase which means that it can cause persistent infection. [8]. 
 
1.2.4 Chlamydophila psitiacci 
Chlamydophila psitiacci is an atypical respiratory pathogen that produces 
psittacosis, a very dangerous lung disease [8].  
Contagion is possible both by human–human and human-bird contact. 
Person-to-person transmission is uncommon, while birds are a very 
dangerous reservoir. In fact, veterinarians, bird breeders and animal 
shopkeepers are at high risk. 
Transmission spreads through direct contact with infected birds, dried 
feces, plumage, respiratory secretions, the cloacae and conjunctiva  
secretions of infected birds [15,16].   
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1.2.5 Coxiella burnetii 
Coxiella burnetii is a causative agent of Q fever. It is zoonotic and is mainly 
present in livestock but also in domestic animals. 
Infections occur through contact with urine, feces and infected animal milk 
where the pathogen is excreted. 
In animals the infections are asymptomatic, while, in humans, the 
bacterium causes acute Q fever with non-specific febrile illness pneumonia 
and hepatitis [17]. 
Q fever is most common in men, and there is a high incidence of CAP 
cases caused by Q fever [8].  
 
1.2.6 Staphylococcus aureus 
Staphylococcus aureus is a gram-positive bacterium, a member of 
micrococcaceae family [18]. It is an opportunistic pathogen, naturally 
present in human resident flora of the nasopharynx in 20% of healthy 
population [19] . It can produce acute infections; in fact, it is responsible for 
both hospital and community-acquired infections [20]. Healthy carriers have 
a higher risk of developing the infection because often, nasal 
Staphylococcus and infecting bacterium have the same genotype [19]. This 
pathogen is extremely versatile and it is able to express different kind of 
virulence factors that help the bacteria to elude the host immune system 
[21]. In particular, biofilm development is an important mechanism for 
defence against the host immune system. Biofilms hide the pathogen, 
masking the phenotype, so it can defend itself from external attacks such 
as antibiotic treatment and immune escape [22].  
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1.2.7 Klebsiella pneumonia 
Klebsiella pneumonia is one of the most common Gram-negative bacilli, 
member of Enterobacteriaceae family [23,24]. It is an opportunistic 
pathogen and therefore represents a risk for immunocompromised patients, 
which often leads to hospitalization. K. pneumonia is naturally present not 
only in human resident flora of nasopharynx, but also colonizes the 
gastrointestinal tract and skin, and it is able to infect the urinary tract 
[24,25]. 
Virulence factors have a key role in severity of infections, and they are 
represented by capsular polysaccharide and type 1 and 3 pili. Capsule 
defends bacteria from phagocytosis, while Pili are involved in biofilm 
production, and this production is directly related to antibiotic resistance  
[24]. 
 
1.2.8 Haemophilus influenzae 
Another commensal of both the upper and lower respiratory tract is 
Haemophilus influenza. It is a gram-negative catalase-positive 
coccobacillus. To date, 2 types are known: non-capsular and capsular 
polysaccharide; in particular, non-capsular types or non-typeable H. 
influenza (NTHi) include a wide variety of genotypes and phenotypes [26]. 
NTHi is implicated not only in the majority of chronic infections of the lower 
respiratory tract such as COPD and cystic fibrosis, but also is associated 
with respiratory tract infections such as otitis media (OM), conjunctivitis, 
sinusitis, and CAP [27].  
 
1.2.9 Streptococcus pneumonia 
Streptococcus pneumonia (Pneumococcus) is an encapsulated lanceolate 
Gram-positive, catalase-negative diplococcus, characterized by a 
surrounding polysaccharide capsule [28]. Moreover, the pneumococcus is a 
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static, asporigenous and facultatively anaerobic bacteria, that is alpha-
hemolytic in the prensence of oxygen and beta-hemolytic in its absence 
[29].  
Streptococcus pneumonia is naturally located in the upper respiratory tract 
[30]. It colonizes the nasopharynx and spreads horizontally causing 
different diseases such as otitis media, sinusitis and pneumonia. 
Pneumococci can migrate in the blood stream causing meningitis, 
peritonitis, skeletal and vascular infections [28,31]. 
Pneumococcal disease is preceded by asymptomatic colonization.  
The host’s immune system plays a key role in the pathogenesis; indeed, a 
low immune response is due to recurrent infection. 
The production of inflammatory factors causes the transition from 
asymptomatic colonization to overt disease.  These factors changes the 
type and number of receptors on target epithelial and endothelial cells, 
increasing affinity for pneumococcal proteins. The bonds between bacterial 
proteins and host cell receptors determine pneumococcal internalization, 
resulting in migration in respiratory epithelium and vascular endothelium 
[30].  
Invasive Pneumococcal diseases are particularly common in younger 
children and in older adults [28,32]. 
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Fig 1 Pathogenetic route for S. pneumoniae infection  
Organs infected by Pneumococcus through the airways. The infection may become 
systemic [30]. 
 
 
 
Virulence factors of S. Pneumonia not only cause damage to the host, but 
also help the pathogen to evade immune defenses. The main virulence 
factor consists in the polysaccharide capsule [32,33]. The structure of the 
capsule is composed of oligosaccharides chains, which in turn consist in 
monosaccharides structures containing from two to eight units [34,35]. After 
invasion it causes attachment to respiratory epithelial cells, and protects the 
pathogen thanks to the important antiphagocytic action on neutrophils [33]. 
Moreover it blocks activation of the alternative complement pathway. 
Different serotypes are characterized by different types of capsule, and this 
determine their different ability to cause invasive disease [28,34].  
An important role in the pathogenesis is played by pneumococcal cell wall 
(CWPS). CWPS induces Interleukine-1 and Tumor Necrosis Factor 
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secretion by monocytes, causing inflammation, inducing activation of 
alternative complement pathway and mast cell degranulation [34]. Another 
important virulence factor is represented by Pneumolysin, an intracellular 
protein with toxic effects on epithelial cells, which stimulates the production 
of inflammatory cytokines and activates the classical complement  pathway 
[34,35]. 
Pneumococcal infection induces phagocytosis activation through 
neutrophils and monocytes. Their recruitment occurs by intra-alveolar 
chemiotaxis. Pneumolysin secretion can inhibit phagocitosys [35]. 
Pneumococcal surface antigens induce antibodies secretion which in turn 
induce opsonization. Opsonization, besides inducing phagocytosis, 
activates the classical and alternative complement pathway [35]. 
 
 
 
 
Table 1. Pneumococcal virulence factors 
Virulence factors Activity 
Polysaccaharide capsule Attachment to respiratory epithelial cells, 
blocks activation of alternative complement 
pathway, evasion of host defense 
CWPS Causes inflammation, induces activation of 
alternative complement pathway and mast 
cells degranulation 
Pneumolysin Toxic effect on epithelial cells, induces 
inflammation, inhibits phagocitosys 
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2. IMMUNE RESPONSE 
 
2.1 Immune responses and respiratory infections 
Immune responses in respiratory tract have a key role in removal 
pathogens introduced by breathing. These dangerous inhalants need to be 
eliminated quickly by the immune system to avoid spreading of infection 
airways and inflammatory response.  
In respiratory tract, the defense mechanism follows a stepwise program 
that ensures minimum necessary response against a microorganism. When 
a pathogen manages to enter in the airway, its initial detection by sensor 
cells that are localized at the site of infection, acting as the first tier of 
defense; the sensor cells promote innate immune responses to clear limited 
infections, and they release first-order cytokines that activate local tissue-
resident lymphocytes, that include innate lymphoid cells (ILCs), innate-like 
lymphocytes, natural killer (NK) cells and tissue-resident memory T (TRM) 
cells. These lymphocytes, in turn, respond to first-order cytokine signals by 
producing second-order cytokines. At each stage of the process, effector 
mechanisms are also activated; these can potentially control the infection 
and thus prevent the activation of subsequent immune responses, limiting 
inflammatory damage [36]. 
 
2.1.1 Mucosal immune system 
The respiratory system is composed of upper and lower respiratory tract 
and respiratory zone. 
In respiratory system, four cell types produce physical and chemical barrier 
against infections: ciliated cells, mucus-secreting goblet cells, club cells and 
basal cells. Ciliated cells and mucus-secreting goblet cells create the 
barrier defense in the larger airways, whereas club cells and basal cells 
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function as regional progenitor cells to replenish the other cell types [37]. 
The defense mechanism is related to airway diameter [36]. 
The respiratory zone is formed by alveoli, among which alveolar type 1 
cells facilitate gas exchange, while alveolar type 2 cells secrete pulmonary 
surfactant. 
Alveolar macrophages reside in the airway space of the alveoli and within 
the mucus of the larger conducting airways. This keeps the respiratory 
mucosa in a state of quiescence. Indeed, alveolar macrophages constantly 
receive negative regulatory cues from airway epithelial cells (AECs). 
Alveolar macrophages are regulated by the airway epithelium through their 
interactions with CD200 (OX-2 membrane glycoprotein), which is 
expressed by type II alveolar cells, with transforming growth factor-β 
(TGFβ) and with interleukin-10 (IL-10). Therefore, in the steady state 
alveolar macrophages function to clear particulates, apoptotic cells and 
cellular debris from the airways in order to maintain homeostatic tissue 
functions [36,38]. 
 
2.1.2 Activation of immune response in respiratory tract 
Upon infection by virus, bacteria, protozoa or fungi, the negative regulatory 
signal due to CD200 and TGFβ are lost.  The immune system is activated 
also by inhalation of allergens or venoms [36]. 
 
2.1.2.1 Antibacterial innate immune responses 
Recognition of conserved features of microbial pathogens by the innate 
immune system is mediated by pattern-recognition receptors (PRRs), which 
detect conserved pathogen-associated molecular patterns (PAMPs). PRRs 
are expressed by different immunocompetent cells, among which 
phagocytic cells, natural killer cells (NK), dendritic cells (DCs). Several 
classes of PRRs have now been identified and characterized including Toll-
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like receptors (TLRs), RIG-I-like receptors (RLRs), C-type lectin receptors 
(CLRs), cytosolic DNA sensors and nucleotide oligomerization domain 
(NOD)-like receptors (NLRs). Toll-like receptors (TLRs) belong to a family 
of transmembrane glycoproteins that serve as PRRs for a variety of 
microbe-derived molecules and stimulate innate immune responses against 
microbes expressing these molecules [39-41]. 
PRRs are characterized by their tissue-specific expression, they can be 
expressed on the cell surface, in intracellular compartments, or secreted 
into the blood stream, that determines two general modes of recognition by 
the innate immune system and immune responses: cell-intrinsic recognition 
and cell-extrinsic recognition. Principal functions of PRRs include 
opsonization, activation of complement and coagulation cascades, 
phagocytosis, activation of proinflammatory signaling pathways, and 
induction of apoptosis [40,41].  
Intracellular pathogens bind PRRs expressed intracellularly and induce 
immunological responses by activation of NF-κB and MAP kinase signaling 
pathways, which leads to the induction of the antiviral type-I IFN genes. 
Cytosolic sensors detect viral RNA and viral DNA in infected cells [42]. 
Indeed, the detection of extracellular pathogens is mediated by PRRs 
expressed on the plasma membranes of macrophages, DCs and other cell 
types. PRRs express on the surface of immunocompetent cells are: TLR1, 
TLR2, TLR4, TLR5 and TLR6, and CLRs, including dectin-1, dectin-2 and 
mincle. These receptors recognize bacterial components and fungal cell 
walls, such as lipopolysaccharides, bacterial lipopeptides, lipoteichoic 
acids, flagellin, glycolipids and β-glucans.  
Particularly, TLR2 and TLR4 are involved in antimicrobial responses.  
TLR2 binds the largest number of bacterial PAMPs. After recognition, TLR2 
forms heterodimers with TLR1 or TLR6. Instead, TLR4 binds LPS. The TLR 
signaling pathway is divided into MyD88-dependent and TRIF-dependent 
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pathways, but both TLR2 and 4 induces proinflammatory cytokine 
secretion. 
 
 
 
Fig 2 TLRs Activation 
TLRs are activated from different bacterial structures. Their activation induces transcriptional 
factors activation producing pro-inflammatory cytokines secretion [39]. 
  
INTRODUCTION 
18 
 
2.1.2.2 Antibacterial adaptive immune response 
Adaptive immune responses to microbes induce effector cells that eliminate 
the microbes and memory cells that protect the individual from subsequent 
infections. CD4 helper T cells produce cytokines that stimulates B cell 
responses, antibody production, macrophage activation, and local 
inflammation. In addition to cytokine secretion, the adaptive immune 
response can also induce cell death through CD8+ cytotoxic T lymphocytes 
(CTLs) activation. CD4 T cells and CD8 T cells function cooperatively in 
defense against intracellular bacteria. Immune system against intracellular 
bacteria and protozoa requires responses by CD8+ T cells and T helper 
type 1 cells (TH1 cell), which develop as a consequence of the 
engagement of TLRs by PAMPs that leads to the production of IL-12 and 
TNF [40]. Against allergens and helminthes, CD4 differentiate into TH2 
secreting IL-10, IL-4, IL-13; the first scenario leads to macrophage 
activation, the second their inhibition [43,44]. On the other hand, the TH17 
subset of helper T cells is specialized in eliminating extracellular bacteria 
and fungal pathogens. The priming of TH17 cells begins with the 
engagement of CLRs such as dectin-1 and dectin-2 expressed by DCs, 
Langerhans cells and macrophages. In addition, the phagocytosis of 
bacteria-infected apoptotic cells induces the production of TGF-β and IL-6 
by DCs, which promotes TH17 cell differentiation [41,45]. 
 
. 
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Fig 3 Innate and adaptive immunity to bacteria  
Innate immunity is the first defense against infection, proinflammatory cytokines secretion 
induce adaptive immune response activation. (Abbas A. K, Cellular and Molecular 
Immunology. 2005) 
 
 
 
2.2 Antibiotic treatment   
Antibiotic treatment of CAP is chosen according to the causative pathogen 
and its antimicrobial resistance. In cases where it is difficult to identify the 
pathogen, it is recommended that antibiotic treatment should cover typical 
and atypical pathogens [8].  
Mainly, intracellular bacteria are treated with macrolides, tetracyclines and 
quinolones. In particularly, severe cases of M. pneumoniae require 
corticosteroid, while for Coxiella burnetii doxycycline is the treatment of 
choice for acute Q fever [8]. 
The drug of choice for S. aureus infections remains penicillin. However, the 
main problem is represent by MRSA, in this case the drug used is 
vancomycin [18].  
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Klebsiella pneumophila is an important nosocomial bacterium. The main 
problem of Klebsiella infections is multidrug resistance, in particular to beta-
lactam. Therefore it is necessary to find appropriate therapeutic options. 
Nowadays  the recommended therapy consist in third and fourth generation 
of cephalosporins, which are more resistant to bacterium beta-lactamase 
[23]. 
Haemophilus influenzae pneumonia is generally treated with macrolides, in 
particular with azithromycin. Furthermore, also in H. influenzae antibiotic 
resistance due to β-lactamase production is very common. Therefore, the 
treatment of CAP patients with beta-lactams would not be effective [46].  
In case of Pneumococcal CAP, the treatment of choice is beta-lactam-
macrolide combinations or fluoroquinolone therapy [32][33]. 
 
 
2.3 Pneumococcal immunization strategies 
Available anti-pneumococcal vaccines contain a mix of purified capsular 
polysaccharides. There are 2 types of vaccine: pneumococcal 
polysaccharide vaccine (PPV23), and pneumococcal conjugate vaccine 
(PVC) [33]. 
PPV23 is an unconjugated vaccine composed of pneumococcal capsular 
polysaccharides from 23 different serotypes [33]. This kind of vaccine is 
recommended from the Advisory Committee on Immunization Practices 
(ACIP) for several risk groups, such as children under 2 years of age or 
people aged between 2 and 65 years old with chronic illness, chronic 
cardiovascular disease or chronic pulmonary disease [28,30]. Vaccination 
strategy also involves the administration of PPV23 in older adults (65-79 
years old) [7]. 
Conjugate vaccines are more recent, and there are several types. 
Pneumococcal conjugate vaccine 7 (PCV7) is recommended for pediatric 
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age groups, in particular infants under 23 months, but also in older children 
with higher risk such as immunocompromised patients or those affected by 
chronic disease [28]. The coverage by pediatric vaccine PCV7, has brought 
a decrease in cases of invasive pneumococcal disease also in adults [7].  
These compounds activate some receptors that identify bacterial products 
or receptors that induce additional stimulation for activation, such as Toll-
like receptors (TLRs) [4]. TLRs belong to a family of transmembrane 
glycoproteins that serve as pattern-recognition receptors (PRRs) for a 
variety of microbe-derived molecules and stimulate innate immune 
responses against microbes expressing these molecules [39,41]. 
Innate immunity acts as a sentinel of the immune system and it is activated 
after recognition of different pathogens. It comprises cells and mechanisms 
that defend the host from infection by other organisms in a non-specific 
manner, including physical barriers, complement cascade, phagocytic cells, 
natural killer cells (NK), dendritic cells (DCs) and cytokines [41]. 
These mechanisms that enhance the innate immune responses also 
stimulate the adaptive immune response [4].  
Several studies have indicated that many infections are reduced 
after immunostimulant treatment [47]. Different kinds of molecules have 
been studied so far and they can be varied in nature. 
 
 
 
3. IMMUNOMODULATORS 
 
Immunomodulators are drug or substance able of stimulating immune 
response against infection. They try to mimic the immune responses 
normally induced by pathogen. This effect is important for their use in the 
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treatment of several disease, especially those related to a decrease in 
immune defenses. Nowadays, many immunostimulants are known and 
marketed. 
Many studies in literature describe their beneficial effects in a great number 
of diseases, in particular, in a meta-analisis study, Del Rio et al. evaluated 
that immunostimulant reduce the incidence of ARTIs by 40% in susceptible 
children [4]. 
The action of immunomodulant on innate and adaptative immune system, 
make them suitable as adjuvant in the antibacterial and antiviral therapy, 
because modulate both local and systemic inflammatory responses to 
improve patient outcome to the treatment [44].   
They can be of various nature: naturals or synthetics or of bacterial origin, 
and each is particularly indicated for the treatment of specific pathological 
condition. 
 
3.1 Bacterial-derived immunomodulators 
Bacterial immunomodulators can contain killed bacteria or bacterial lysate; 
these compounds mimic the intrusion of a pathogen into the body, 
activating both innate and adaptive immunity [48]. 
Bacterial antigens reach Peyer’s patches in Gut lumen, where they induce 
dendritic cells (DCs) activation, increase phagocytosis and B and T cells 
stimulation. Simultaneously they cause humoral response through cytokine 
secretion [48]. 
Among bacterial immunomodulators, different compounds are known. 
 
- Broncho Vaxom (OM-85 BV) is a bacterial immunomodulator composed 
of lysates of 8 of the most common bacteria strains in upper respiratory 
tract infection, including Haemophilus influenza, Streptococcus 
pneumoniae, Klebsiella pneumoniae, Klebsiella ozeanae, Staphilococcus 
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aureus, Streptococcus viridans, Streptococcus pyogenes, and Neisseria 
catarrhails [48,49]. It regulates innate immunity by acting on macrophages, 
neutrophils and proinflammatory cytokines production [48], while it acts on 
acquired immune response by stimulating lymphocytes proliferation and 
immunoglobulin synthesis [49]. Luan et al. demonstrated that OM85-BV 
stimulated IL-1β, IL-6, and TNF-α production. IL-1β, IL- 6, and TNF-α are 
critical inflammatory cytokines predominantly produced by macrophages, 
and have pleiotropic effects on regulating the immune response and acute-
phase reaction [49]. 
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Fig 4 Broncho-Vaxom: mechanism of action 
OM-85 induces proinflammatory cytokine secretion through TLR2 and TLR4 activation [49]. 
 
 
 
- Luivac (LW 50020) is a bacterial lysate immunomodulator consisting of 
several bacteria that typically cause respiratory infections such as 
Staphylococcus aureus, Streptococcus mitis, Streptococcus pyogenes, 
Streptococcus pneumoniae, Klebsiella pneumoniae, Moraxella 
(Branhamella) catarrhalis, Haemophilus influenza. 
This immunostimulant induces T lymphocytes proliferation, and causes an 
up-regulation of numbers of CD4 and CD8 and memory cells . As regards 
cytokinesecretion, [48]. Animal studies also demonstrated that oral 
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administration of LW 50020 resulted in increased production of specific IgA 
[50]. 
 
- Polyvalent mechanical bacterial lysate (PMBL) is a mix of different 
bacteria, such as Staphylococcus aureus, Streptococcus pneumoniae, 
Streptococcus pyogenes, Hemophilus influenzae, Moraxella catarrhalis and 
Klebsiella pneumoniae. The main action of this compound is observed in 
maturation of both dendritic cells (DCs) and plasmacytoid DCs. 
Furthermore, it induces secretion of interleukin 2 (IL-2), interleukin 10 (IL-
10), interleukin 12 (IL-12) and interferon gamma (IFN-γ) [51]. Ricci et al. 
reported that treated patients were able to avoid not only infectious disease 
associated to the microbes present in the administered mixture, but also 
other infections, such as virus infections [51]. 
 
- Ribomunyl (D53) is a ribosomal extract containing immunogenic 
ribosomes of four bacteria responsible for recurrent respiratory infection: 
Klebsiella pneumoniae, Streptococcus pneumoniae, Streptococcus 
pyogenes and Haemophilus influenza. Ribosomal components are 
associated with the proteoglycans from cell membrane of Klebsiella 
pneumoniae. D53 stimulates lymphocyte, natural killer (NK) and DCs. 
Particularly on DCs, D53 up-regulates CD83, CD86 and HLA II expression 
[48,52]. D53 increases the production of specific antibody against each of 
the germs for which the ribosomes were present in D53. Pujol et al. 
demonstrated that D53 stimulates mouse spleen cells to produce IL-1, 
induces differentiation of mouse B cells into immunoglobulin-secreting cells, 
and enhances NK activity [52].    
 
- Biostim (RU 41740) is an immunomodulator composed of glycoproteins 
complex extract from Klebsiella pneumophila. The compound stimulates 
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the activity of phagocytic cells and increase antibody secretion by B cells 
[53]. 
In vitro studies conducted by Aloui et al. have also shown its effect on 
human bronchial epithelial cells (HBEC), where it induces secretion of 
granulocyte-monocyte secretion factor (GM-CSF), IL-1, IL-6 and IL-8 [54]. 
 
 
 
 
Fig 5 Mechanism of action of the oral immunostimulators [48]. 
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3.2 Natural substances 
Natural immunomodulators are compound normally present in nature. They 
can be extracted from the plants or introduced with alimentation. Among 
these, Pleuran is an insoluble β glucan isolated from Pleutorus ostreatus. 
Its immunomodulatory properties render the host more resistant to 
infections. Pleuran treatment induces physiological maturation of the 
humoral immune response and an increase of NK cell number [55]. Results 
of Jesenak et al. showed a significant decline in respiratory morbidity, 
including a decrease in the number of RRTIs in the treated group compared 
to placebo group.  In particular, they observed significant result after 
several months from the beginning of the therapy. They observed an 
increase of IgG and IgM in treated group of children, that is maintained for 
all duration of the study [55]. 
 
- Vitamin D influences innate immune function through a number of 
mechanisms that include production of antimicrobial peptide (AMP) and of 
intracellular reactive intermediates. It acts on the maturation of DCs, and 
induce B-cell differentiation and proliferation. It has also been found to 
affects T-cell differentiation, shifting polarization to preferentially TH2 cell 
development (with IL-4, IL-5, and IL-10 production) [56]. Hoe et al. 
investigated the effects of 1,25(OH)2D3 (Vitamin D) on ex vivo PBMCs 
stimulated with Gram-positive (pneumococci) or Gram-negative (LPS) 
bacterial ligands. In the study, they found that pre-treatment with 
1,25(OH)2D3 reduced the levels of TNF-α, IFN-γ, IL-1β, and IL-8 in 
supernatants in response to heat-killed pneumococcal serotype 19F 
(HK19F) and LPS stimulation, while only TNF-α and IL-1β were reduced in 
monocytes [57]. 
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- Probiotics including Lactobacillus and Bifidobacterium, produce different 
types of antibacterial substances and stimulate host immune system 
through diverse mechanisms. They interact with intestinal epithelial cells 
(IECs), mucosal dendritic cells (DCs) and macrophages through diverse 
way. Pattern recognition receptors (PRRs) including Toll-like receptors, 
(TLRs) play essential roles in recognition and delivery of signaling 
cascades, which mediate different gene expression profiles [58]. The anti-
inflammatory effect of probiotics is generally attributed to their direct 
interactions with pathogenic microbes or their cross-talk with host cells. 
Castillo et al. showed effects of L. casei administration in mice infected by 
Salmonella. Probiotics administration reduced mortality in infected mice. 
Post infection, they analysed pro-inflammatory cytokines production in cells 
isolated from Peyer’s patches. After infection, treated mice increased TNF-
α and IFN-γ. At day seven and ten post infection, the probiotic 
administration was able to maintain this production. The same trend was 
maintained from IL-6 and IL-10. Furthermore, they analysed also probiotic 
effects on TLRs expression. Results showed that treated mice increase 
TLR2, TLR4, TLR5  and TLR9 expression after seven days of infection [59]. 
 
3.3 Synthetic compounds 
The synthetic immunomodulators are completely alien to the natural world, 
they are obtained by chemical synthesis from industrial processes. 
Several studies demonstrated their safety and absence of adverse effects. 
 
3.3.1 Pidotimod 
Among synthetic immunostimulators Pidotimod has long been studied. 
Pidotimod (3-L-pyroglutamyl-L-thiaziolidine-4 carboxylic acid) is a 
synthetic dipeptide molecule with immunological activity.  
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Fig 6 Pidotimod structure 
 
 
 
 
In vivo and in vitro studies show that Pidotimod (PDT) acts on both 
adaptive and innate immunity [60].  Pidotimod is rapidly absorbed by the 
gastrointestinal tract with a bioavailability of 45%. The plasma half-life is 
four hours with poor metabolism and renal elimination of the unmodified 
molecule [61]. Giagulli et al. have shown by in vitro studies that PDT 
induces dendritic cells (DCs) maturation, up-regulates the expression of 
HLA-DR and of co-stimulatory molecules such as CD83 and CD86, 
stimulates DCs to release pro-inflammatory molecules driving T-cell 
proliferation and differentiation towards TH1 phenotype, enhances NK cell 
functions and promotes phagocytosis [62]. Studies carried out on mouse 
bone marrow cells, have instead demonstrated that PDT facilitates M2 
polarization of bone marrow-derived macrophages (BMDMs) [63]. A second 
study about BMDMs evaluated synergic effects of PDT and methionine 
encephalin (MENK) on activation and maturation. When treated with both of 
them, DCs presents more maturation than those treated with either MENK 
or PTD alone. Costimulatory molecules CD80, CD86, CD40, followed by 
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antigen-presenting molecules MHC-II and CD83, increased significantly 
[64]. DCs have a key role in immune response; indeed, they are potent 
antigen presenting cells (APCs) with macrophages and B lymphocytes. 
APCs present antigens to T lymphocytes activating humoral response.  
Pidotimod also has effects on different transcription factors; in fact on 
extracellular-signal-regulated kinase (ERK1/2) and nuclear factor-kappa B 
(NF-kB), PDT increases the expression of toll-like receptors (TLRs) [65,66]. 
TLR response also involves mechanisms of acquired immunity, therefore 
playing a key role in linking innate and adaptive immune responses. 
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Fig 7 PDT mechanism of action 
PDT acts on both, innate and adaptive immunity, activating DCs and proinflammatory 
cytokines secretion [60].  
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Zuccotti et al. have described PDT effects in children with Down syndrome 
(DS). 
In DS there is a reduction of circulating B-cells, a decrease of CD4 T 
lymphocytes and an increase of CD8 T cells. Therefore, these children are 
more susceptible to developing ARTIs. Furthermore, in children with 
Down’s syndrome, up to the age of 18, RTIs are the second leading cause 
of death [67]. PDT administration reduces the rates of ARTIs in children 
with DS [2]. Data obtained from Mantia et al. demonstrated beneficial 
effects of pidotimod also in prophylaxis on upper respiratory tract infections 
in children with DS. In this study, subject treated with pidotimod showed a 
statistically significant improvement in mucosal hyperemia, nasal secretions 
and nasal respiratory obstructions [68]. 
Mameli et al. have observed PDT effects in children with predisposing 
factors of ARTI. Statistical analysis showed a 22% reduction of the rate of 
ARTIs in children who received PDT compared to those who received a 
placebo [3]. Pidotimod effects were described in several diseases. Li et al. 
investigated the status of T lymphocytes  CD4, CD8, and B lymphocytes 
NK cells, and the differential secretion of the inflammatory interleukin-6 (IL-
6) and interleukin-8 (IL- 8) and tumor necrosis factor-α (TNF-α) in children 
with Tourette’s syndrome (TS). They hypothesize that there is an   
association between TS and streptococcal infection, therefore an immune 
therapy may help improve immune dysregulation in these patients.  
Patients with TS had decreased numbers of CD4+ T cells with a depressed 
CD4+/CD8+ ratio. By contrast, the numbers of NK cells were increased. 
Furthermore, they found reduced expression of both IL-6 and IL-8 while the 
level of TNF-α was increased. 
Following 8 weeks of treatment with pidotimod, it was observed that the 
numbers of T lymphocyte subpopulations and NK cells returned to a more 
INTRODUCTION 
33 
 
normal frequency.. Serum levels of pro-inflammatory IL-6 and IL-8 also 
increased, but still lower than healthy controls [69].  
PDT could be a promising treatment for many immunological diseases due 
to its immunomodulatory properties. Jin et al. presented a case report of 
oral lichen planus treated with PDT.  
Oral lichen planus is an immunological disease in which T lymphocytes 
produce cytotoxic activity against epithelial cells. In the case report the 
lesion and his symptoms improved remarkably after oral administration of 
orally PDT 0.4 g twice a day for 1 month, followed by intramuscular 
injection of bacillus Calmette-Guerin polysaccharide nucleic acid (BCG-
PSN), 1 mL, every other day for another month to improve immune function 
[70]. 
Huo et al., instead, showed PDT effects on toxoplasmosis prevention. They 
used a murine model of reactivated toxoplasmosis induced by 
cyclophosphamide (CY) and investigated the efficacy of pidotimod as an 
oral preventive agent. Results showed that PDT treatment significantly 
alleviated the parasitemia induced by the immunosuppressive agent. Thus, 
the beneficial efficacy of pidotimod administration may prevent the viral 
reactivation [71]. 
Data described in literature suggest a promising use of PTD as adjuvant in 
the vaccines. In particular Zhao et al. studied pidotimod effects as an 
adjuvant on UV-attenuated Toxoplasma gondii. Results indicate that co-
administration of pidotimod can further enhance the potency of UV-T. 
gondii vaccine [72]. 
Di Renzo et al. evaluated in vitro effect of Pidotimod on some cellular 
immune responses in neoplastic patients. Cancer patients showed an 
impairment in lymphomonocyte IL-2 production in response to the same 
mitogens. Reduced IL-2 production might be important because it might 
contribute to the cancer spreading, especially affecting LAK and NK cells, 
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which are involved in the immune response against tumors. The in vitro 
addition of Pidotimod increased IL-2 production, However, this data 
suggest that Pidotimod might be used as an adjunctive immunotherapy in 
cancer patients [73]. 
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Several attempts to improve immune function in young children and adults 
have been made using alternative medicines (e.g., plant preparations), 
dietary supplements (e.g., vitamins C and D, zinc, cod liver oil and 
polyunsaturated fatty acids), and other preparations such as inosine 
pranobex, probiotics, bacterial lysates and pidotimod (PDT). In only a few 
cases, scientific evidence of positive effects was found. However, 
encouraging results have been collected with PDT treatment, a synthetic 
dipeptide molecule (3-l-pyroglutamyl-l-thiazolidine-4carboxilic acid) that 
seems to have immunomodulatory activity on both innate and adaptive 
responses. Higher expression of TLR2 proteins, induction of dendritic cell 
maturation accompanied by an increased release of pro-inflammatory 
molecules, upregulation of the expression of HLA-DR, stimulation of T 
lymphocyte proliferation and differentiation toward a TH1 phenotype, 
inhibition of thymocyte cell death and promotion of phagocytosis have all 
been demonstrated in in vitro studies in both animal and human subjects 
[66,73,74]. Moreover, in vivo studies have demonstrated that long-term 
prophylactic use of PDT can be of benefit in children with RRTIs, reducing 
the total number of new infectious episodes and the consequent use of 
drugs, including antibiotics [75]. A recent Italian study showed that PDT 
treatment 400 mg/day for 2 months was able of significantly reducing the 
number of children with upper and lower airways symptoms, and 
medications use, increasing school attendance, and reducing pediatric 
visits for RRTIs [76]. Finally, in subjects with Down syndrome, it was found 
that the response to the influenza vaccine administered at the beginning of 
a 90 day-PDT course was different from the response in untreated children, 
suggesting a preferential activation of effector mechanisms and a potential 
beneficial effect of immunization [2]. So far, the effects of PDT on the 
immune system have only been studied in vivo after long-term 
administration to evaluate whether its immunomodulatory activity might 
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prevent the development of infections. No data are available on the 
immunological impact of PDT when given during an acute disease. 
Information regarding this could be useful to understand whether this drug 
could positively influence the clinical course of an acute infection.  
This study was planned to evaluate the immunomodulatory activity of PDT 
administered together with standard antibiotic therapy in children and adults 
hospitalized for community-acquired pneumonia (CAP). 
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1. STUDY DESIGN 
 
1.1 Pediatric patients 
A randomize double-blind controlled study was conducted in 20 pediatric 
patients from the Pediatric Highly Intensive Care Unit of the University of 
Milan, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, 
Milan, Italy between November 1, 2013 and April 30, 2014. 
It was approved by the Ethics Committee of the Fondazione IRCCS Ca’ 
Granda Ospedale Maggiore Policlinico, Milan, Italy. 
Written informed consent was obtained from the parents or legal guardians 
of all study participants, and in the case of patients aged ≥7 years, written 
consent from the children was also collected. 
Children enrolled in the study were children aged 3-14 years with clinical 
signs such us tachypnea and abnormal breath sounds and a chest 
radiograph consistent with uncomplicated CAP. Complicated CAP was 
defined as the presence in a chest radiograph of more than one of the 
following conditions: parapneumonic effusion, defined as loculated pleural 
fluid; any pleural fluid parameters consistent with empyema; atelectasis; 
and necrotizing pneumonia [77]. The CAP diagnoses were all confirmed by 
chest radiographs evaluated by an independent expert radiologist who 
classified the findings as alveolar pneumonia, non-alveolar pneumonia or 
no pneumonia in accordance with the World Health Organization criteria for 
the standardized interpretation of pediatric chest radiographs for the 
diagnosis of pneumonia [78]. 
Upon enrollment, detailed information regarding children’s demographics, 
clinical history and the characteristics of the disease were collected 
together with a blood sample for the evaluation of laboratory variables, 
including white blood cell (WBC) counts, C-reactive protein (CRP) and 
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procalcitonin (PCT) levels. A portion of the blood sample obtained at the 
time of recruitment (T0) (i.e., before therapy administration) was also used 
for the immunological analysis described below. The enrolled children were 
randomly assigned in a 1:1 ratio and according to a computer-generated list 
to receive either standard antibiotic therapy with cefotaxime (100 mg/kg/ 
day in 3 daily doses, i.v.) plus clarithromycin (15 mg/kg/ day in two daily 
doses, orally) (control group) according to the guidelines for the treatment 
of pediatric CAP prepared by the Italian Society of Pediatrics [79] or the 
same antibiotics plus PDT (Axil®, 400 mg/day in two daily doses, orally) 
(PDT group). In both groups, cefotaxime was administered for 4 days and 
then followed by amoxicillin-clavulanate (80 mg/kg/day in 3 daily doses, 
orally, for 6 days), and clarithromycin was administered at the same dosage 
for 14 days; in the PDT arm, PDT was given at the same dosage for 14 
days. Blood samples for the evaluation of immunological parameters were 
drawn at T3 and T5 (i.e., 3 and 5 days after the initiation of therapy) as well 
as at T21 (i.e., 7 days after the therapy ended). All of the information was 
registered in an electronic database.  
 
 
 
 
Table 2 Main demographic, clinical and laboratory characteristics at baseline in 20 
children hospitalized for CAP according to the use of pidotimod plus antibiotics or 
antibiotics only [80]. 
 
Characteristic All 
children 
(n=20) 
Pidotimod+ 
antibiotics (n=10) 
Antibiotics only 
(n=10) 
p-value 
Demographcs 
    
Age (yars) 
    
Mean (SD) 4.6 (1.9) 4.4 (2.0) 4.7 (1.8) 0.70a 
Sex (%) 
    
Male 14 (70) 7 (70) 7 (70)  
Female 6 (30) 3 (30) 3 (30) 1 
Etniticy (%) 
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Caucassian 17 (85) 8 (80) 9 (90)  
Non-Caucasian 3(15) 2 (20) 1 (10) 0.99b 
Parenthal smoking habitb 
(%)     
Both non-smokers (%) 13 (65) 6 (60) 7 (70) 
 
At least one smoker (%) 7 (35) 4 (40) 3 (30) 0.99b 
Exclusive breastfeeding≥3 
monthsc 
    
Yes (%) 11 (58) 4 (40) 7 (78) 
 
No (%) 8 (42) 6 (60) 2 (22) 0.17b 
Diagnosis of allergy (%) 
    
Yes 18 (90) 9 (90) 9 (90)  
No 2 (10) 1 (10) 1 (10) 1 
Respiratory infections in 
the previous 6 months (%) 
    
At least one 13 (65) 5 (50) 8 (80)  
None 7 (35) 5 (50) 2 (20) 0.35b 
Use of antibiotics for 
respiratory infection in the 
previous 6 months (%) 
    
Yes 4 (20) 2 (20) 2 (20)  
No 16 (80) 8 (80) 8 (80) 1 
Clinical characteristics     
Fever (>=37.8°)c (%) 
    
Yes 8 (42) 5 (56) 3 (30) 0.37b 
No 11 (58) 4 (44) 7 (70)  
Coughc (%) 
    
Yes 18 (95) 8 (89) 10 (100)  
No 1 (5) 1 (11) 0 (0) 0.47b 
Dyspneac (%) 
    
Yes 4 (21) 2 (22) 2 (20)  
No 15 (79) 7 (78) 8 (80) 0.99b 
Rhonchi (%) 
    
Yes 1 (15) 1 (10) 0 (0)  
No 19 (95) 9 (90) 10 (100) 0.99b 
Rales (%) 
    
Yes 16 (80) 7 (70) 9 (90)  
No 4 (20) 3 (30) 1 (10) 0.58b 
Wheezes (%) 
    
Yes 4 (20) 3 (30) 1 (10)  
No 16 (80) 7 (70) 9 (90) 0.58b 
SpO2<92% (%) 
    
Yes 7 (35) 2 (20) 5 (50)  
No 13 (65) 8 (80) 5 (50) 0.35b 
Laboratory results     
White blood cell count 
(cells/µL) 
    
Mean (SD) 13.154 
(6.512) 
13.176 (6.708) 13.132 (6.672) 0.97a 
CRP (mg/L) 
    
Mean (SD) 5.95 
(6.58) 
5.82 (5.02) 6.07 (4.25) 0.82a 
PCT (ng/mL) 
    
Mean (SD) 0.40 
(0.84) 
0.42 (0.89) 0.38 (0.84) 0.96a 
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1.2 Adult patients 
This pilot multicenter randomized double-blind study was conducted in 16 
adult patients with a diagnosis of pneumonia enrolled from two major 
hospitals in Milano: Fondazione IRCCS Ca’ Granda Ospedale Maggiore 
Policlinico, and University of Milan Ospedale San Paolo. 
Patients (11 males, and 5 females mean age 56.6 ± 7.7 years) affected by 
CAP with a pneumonia severity index (PSI) score III or IV and/or a CURB-
65 0-2, were included in the study. 
Exclusion criteria included: a) hospitalization in the previous 15 days; b) a 
diagnosis of active tuberculosis or infection with fungi; and c) a condition of 
immunosuppression, including HIV infection, neutropenia, 
immunosuppressive therapy, chemotherapy, transplantation, cytotoxic 
therapy, and chronic systemic steroid therapy. The following data were 
recorded: demographics; past medical history; severity of symptoms on 
admission; pneumonia severity index (PSI) and CURB-65 score; physical, 
laboratory, and radiological findings on admission; microbiological data; 
empiric antibiotic therapy; time to clinical stability, in-hospital mortality. Nine 
patients were randomized to the active arm and treated with PDT (Axil® 
800mg, 2 daily doses for 10 days) in combination with the standard 
antibiotic treatment (Levofloxacina 500mg b.i.d); seven patients were 
randomized to receive the standard antibiotic therapy (Levofloxacina 
500mg b.i.d). Immunological analyses were performed at different time 
points: T0 (at recruitment, before therapy administration) as well as T3 and 
T5 (3 and 5 days after therapy initiation). 
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2. SAMPLE COLLECTION 
 
2.1 PBMC isolation 
Whole blood was collected by venipuncture in Vacutainer tubes containing 
EDTA (ethylenediaminetetraacetic acid) (Becton Dickinson, Rutherford, NJ, 
USA). Samples were centrifugated 1400 rpm for 10 minutes, plasma 
obtained was collected and stored at -20°C for subsequent analysis. 
The remain sample, composed by erythrocytes, PBMCs, granulocytes, and 
platelets, was diluited in PBS (Phosphate buffered saline) (PBI 
International, Milano, Italy) and separated thanks to a density-gradient 
centrifugation on lymphocyte separation medium (Ficoll-Hypaque) 
(Cedarlane Laboratories Limited, Hornby, Ontario Canada) for 25 minutes 
at 2300 rpm. PBMCs are localized between the phase of fycoll-hypaque 
and the phase including granulocytes and eritrocytes, they are collected 
and washed twice in PBS for 10 minutes at 1900 rpm. Cellular pellet was 
washed twice in PBS, and cell number and cellular vitality were 
determinated using an automatic cell counter.  
 
 
 
 
Fig.8 PBMCs separation [81]. 
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2.2 Cell count 
Cell count was performed with the automated cell counter ADAM-MC 
(Digital Bio, NanoEnTek Inc., Corea). ADAM-MC automatic cell counter 
measures total cell numbers and cell viabilities by cutting edge detection 
technologies. Instead of tryphan blue staining, which can lead to inaccurate 
data, ADAM-MC utilizes two sensitive fluorescence dye staining solution, 
AccuStain Solution T (Propidium lodide/lysis solution) and AccuStain 
Solution N (Propidium lodidel/PBS). AccuStain Solution T allows plasma 
membrane distruption and nucleus staining for measurement of total cell 
concentration. AccuStain solution N allows stain of non-viable cells, thus 
leaving viable cells completely intact. A 532 nm optic laser is automatically 
focused onto the cell solution inserted into a disposable microchip and cell 
analysis is made by a CCD detection technology.  
The image results were automatically processed, generating the count of 
non-viable and viable cells and the percentage of viability, which was 
displayed on the front of the instrument.  
 
3.4 PBMC stimulation 
PBMCs were incubated for 18 either without any stimulus, or in the 
presence of a mix of 8 main Pneumococcal polysaccharides normally 
present in the vaccine (10µl/ml) (ATCC® Pneumococcal polysaccharide 
type 23, 4, 14, 9, 57, 6A, 3, 5, LGC Standards, Milan, Italy) or of the 
lipopolysaccharide (LPS Sigma-Aldrich, St. Louis, MO, USA) (2µg/ml). Anti-
CD 28 antibody (R&D Systems, Minneapolis, MN, USA) was added during 
incubation (2 µg/mL) to facilitate costimulation. 
After 3 hours-stimulation, RNA was extracted from PBMCs by acid 
guanidinium thiocynate-phenol-chloroform method. For cytokine analysis, 
10 µg/ml Brefeldin A (Sigma-Aldrich) was added to cell cultures. After 18 
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hours-stimulation, PBMCs were stained for immunophenotype and 
intracellular cytokines secretion analyses performed by flow cytometry.  
 
3. FLOW CYTOMETRY ANALYSIS 
 
All flow cytometry analyses were performed using a Gallios flow cytometer 
(Beckman-Culter, Miami, FL, USA) equipped with a double 15-mV argon 
ion laser with a wavelength of between 488 and 638 nm, interfaced with an 
Intercorp computer. Green fluorescence from FITC (FL1) was collected 
through a 525 nm band-pass filter; orange-red fluorescence from PE (FL2) 
was collected through a 575 nm band-pass filter; Texas red fluorescence 
from ECD (FL3) was collected through a 620 nm band-pass filter; red 
fluorescence from PECy5 (FL4) was collected through a 695 nm band-pass 
filter; far red fluorescence from PECy7 (FL5) was collected through a 755 
nm band-pass filter. Data were collected using linear amplifiers for forward 
and side scatter and logarithmic amplifiers for FL1, FL2, FL3, FL4 and FL5. 
Samples were first run using isotype controls or single fluorochrome-
stained preparations for color compensation. For each analysis, 30,000 
events were acquired and gated for CD14 and CD11c expression and SSC 
properties. 
 
3.1 TLR expression on monocytes 
After 18 hours of stimulation, PBMCs were resuspended in PBS and 
stained for surface mAb CD14 PECy5, TLR4 PE, TLR2 FITC (Beckman-
Coulter, Fullerton, CA, USA). After 15 min incubation at room temperature 
in the dark, cells were washed and fixed in 1% paraformaldehyde (Sigma-
Aldrich, St. Louis, MO, USA) in PBS. 
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3.2 Dendritic cell maturation 
Stimulated PBMCs were resuspended in PBS and stained for surface mAb 
CD11 PECy7, HLA-DR II PECy5, CD86 PE, CD80 FITC (Beckman-Coulter, 
Fullerton, CA, USA) for 15 min at room temperature in the dark. PBMCs 
were washed and fixed in 1% paraformaldehyde (Sigma-Aldrich, St. Louis, 
MO, USA) in PBS. 
 
3.3 Intracellular cytokine expression 
After stimulation, PBMCs were washed in PBS and stained for CD14 
PECy5, and CD11 PECy5 (Beckman-Coulter, Fullerton, CA, USA). After 15 
min incubation at room temperature in the dark, cells were washed and 
fixed in 1% paraformaldehyde (Sigma-Aldrich, St. Louis, MO, USA) in PBS. 
Cells were then permeabilizated with saponin 0.5% (Sigma-Aldrich, St. 
Louis, MO, USA) and stained for TNF-α PE and IL12 FITC (eBioscence, 
San Diego, CA, USA). After 45 minutes incubation at 4°C in the dark, cells 
will be washed and fixed in 1% paraformaldehyde in PBS. 
 
4. GENE ANALYSIS 
 
4.1 RNA extraction 
RNA was extracted from 1x106 cultured PBMCs by using acid guanidium 
thiocyanate-phenol-chlorophorm metod. RNAzol B reagent (Duotech, 
Milan, Italy), a monophase solution containing phenol and guanidine 
thiocyanate, was used. Samples were lysed in 200 µl of RNAzol B to which 
20% of chlorophorm was added. Samples were centrifugated 13000 g for 
15 minutes at 4°, to efficiently remove DNA and proteins from the acqueous 
phase containing RNA. To the acqueous phase, collected and transferred 
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to a sterile tube, was added an equal volume of isopropanol, sample were 
stored at -20°C overnight to allow complete RNA precipitation. 
The day after, samples were heated at 4°C for 15 minutes and 
centrifugated at 13000 g for 15 minutes. Supernatant was removed and 
RNA pellet was washed twice with 75% ethanol (100 µl). 
Once the supernatant was removed, pellet was dried under laminar flow 
cabin.  
 
4.2 DNasi treatment and retrotranscription (RT) 
RNA was dissolved in RNase–free water, and purified from genomic DNA 
with TURBO DNase (Applied Biosystems/Ambion, Austin, TX, USA), a 
genetically engineered from of bovine DNase I with greater catalytic 
efficiency than conventional DNase I at higher salt concentrations and 
lower DNA concentration. A reaction mixture, containing 1µg of RNA, Turbo 
DNase 1U and TURBO DNase buffer, were incubated 30 minutes at 37°C. 
Then DNase was inactivated by EDTA 60 mM. 
1 µg of RNA was reverse transcribed into first-strand cDNA in a 20 µl final 
volume. A reaction mixture, containing 1 µM random hexanucleotide 
primers, 1 µM oligo dT and the RNA, was heated at 70°C for 5 Minutes to 
melt secondary structure within the template. The mixture was immediately 
cooled on ice to prevent secondary structure from reforming. A dNTPs mix, 
200 U Moloney murine leukemia virus reverse transcriptase (M-MLV RT), 
20 U Recombinant RNase inhibitor and M-MLV 5X reaction buffer were 
added (Promega, Fitchburg, Wi, USA). The reaction mix was incubated 60 
minutes at 42°C and then heated 5 minutes at 95° C to inactivate the RT. 
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4.3 Real Time PCR Arrays 
 
4.3.1 Human Antibacterial Response PCR Array 
The antibacterial response signaling pathway was analyzed using a real-
time polymerase chain reaction PCR array including a set of optimized real-
time PCR primer assays on 96-well plates (SABiosciences Corporation, 
Frederick, MD, USA). This approach permits the monitoring of the mRNA 
expression of 84 genes (Table 3) involved in the innate immune response 
to bacteria plus five housekeeping genes, following the procedures 
suggested by the manufacturer. Controls were also included on each array 
for genomic DNA contamination, RNA quality and general PCR 
performance. The results were analysed by SABiosciences online software. 
Only targets showing at least a 2-fold modulation were considered 
significative. 
The experiments were performed on pools of patients divided into 
treatment and stimulation conditions groups. Thus, results represent the 
mean value of the different targets analysed in each group.  
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Table3. Complete list of antibacterial responses signaling pathway (SABiosciences) 
 
 
 
3.4 Statistical analysis 
Data were analyzed according to standard statistical tests; t test were 
performed to compare groups during the treatment. Procedures were 
based on parametric analysis. 
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1. PEDITRIC PATIENTS 
 
1.1 Pneumococcal-specific immune responses 
The expression of surface molecules and cytokine secretion were assessed 
upon PBMC stimulation in vitro with pneumococcal polysaccharides.  
PBMCs were analysed at different time points (T0, T3, T5 and T21) in   
PDT group compared to controls. 
Results showed that PDT modified on dendritic cells and monocytes 
functions. 
 
1.1.1 Dendritic cell activation 
Figure 8 shows the results of dendritic cell (DC) maturation analysis 
according to treatment arms DCs were characterized by analyzing the 
expression of surface markers associated with cell activation and 
maturation (HLA-DRII) and costimulatory molecules (CD80, CD86).  
No differences were observed between the two groups at enrolment. An 
increased CD80 expression on the CD11c+ cells were reported in PDT 
group compared to control group at T3, T5 and T21, (p<0.05, p<0.001, 
p<0.01 respectively) (Figure 9, panel A). The percentage of CD86-
expressing CD11c+ cells was significantly higher at T5 and T21, with an 
increase of 22% and 27%, respectively (p=0.05) in PDT-treated patients 
compared to control patients (Figure 9, panel B). Similar trend was 
observed for HLA-DRII expression on DCs, at T5 and T21 (p=0.001 and 
p=0.008) (Figure 9, panel C). Finally, analysis of co-expression of HLA-
DRII, CD80 and CD86 on DCs showed similar differences at T5 and T21 
between the two groups of CAP patients (p=0.0042, p=0.0017, 
respectively) (Figure 9, panel D). 
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Fig.9 Activation of DCs.  
Percentages of pneumococcal-stimulated CD80- (A), CD86- (B), HLA-DRII- (C), and CD80, 
CD86, and HLA-DRII-expressing dendritic cells (CD11c+) (D). Surface molecules are shown 
at baseline and in response to therapy (T1, T5, T21) in children with community-acquired 
pneumonia (CAP) treated with antibiotics plus pidotimod and in controls treated with 
antibiotics only. For each analysis, 30,000 events were acquired and gated on CD11c 
expression and side scatter properties. Mean values + SEM and statistically significant 
differences are indicated. 
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1.1.2 TLRs expression on monocytes surface  
Activation of monocytes (CD14+ cells) via TLRs was also evaluated after 
stimulation of PBMCs with pneumococcal polysaccharides. As shown in 
Figure 10, TLR2 expression on CD14+ cells was significantly higher in PDT 
group compared with control group at 5 and 21 days after treatment 
initiation, with a significant p value for the comparison across time-
treatment groups (p=0.011, p=0.049) (Figure 10, Panel A). TLR4 
expression showed a statistical significance at T21 with an increase of 23% 
(p=0.017) (Figure 10, Panel B). Data obtained by analyzing TLR2 and 
TLR4 co-expression on CD14+ cells mirrored the single-marker evaluation, 
(T21: p=0,017) (Figure 10, Panel C). 
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Fig.10 Percentage of TLR expression on monocytes.  
TLR2 (A), TLR4 (B), and TLR2/TLR4-coexpression (C) expression on CD14+ cells are 
shown at baseline and in response to therapy in children with community-acquired 
pneumonia (CAP) treated with antibiotics plus pidotimod and in controls treated with 
antibiotics only. For each analysis, 30,000 events were acquired and gated on CD14 
expression and side scatter properties. Mean values + SEM and statistically significant 
differences are indicated. 
 
  
CD14/TLR4
T0 T3 T5 T21
0
20
40
60
CTL
PDT
p=0.011
%
 
o
f p
o
si
tiv
e 
ce
lls
CD14/TLR-2
T0 T3 T5 T21
0
5
10
15
20
25
30
CTL
PDT
p = 0.011
p = 0.049
%
 
o
f p
o
si
tiv
e 
ce
lls
CD14/TLR2/TLR4
T0 T3 T5 T21
0
10
20
30
40
CTL
PDT
p=0.017
%
 
o
f p
o
si
tiv
e 
ce
lls
A
B
C
RESULTS 
55 
 
1.1.3 Cytokine secretion by immunocompetent cells 
Analyses of cytokine release from DCs revealed that the percentage of 
TNFα- or IL12-producing CD11c+ cells was higher in the PDT group 
compared to the control group at days 5 and 21, with a significant p for both 
cytokines across time (Figure 11, Panels A and B) (p=0,010, p=0,008, 
p=0,01, p<0,001). A similar trend can be observed in TNFα and IL12-
producing DCs (p=0,049, p=0,037) (Figure 11, Panel C). 
Cytokines were detected also in monocytes. In CD14+ cells, TNFα and IL-
12 producing cells percentage increased at day 5 and day 21 in treated 
group compared to control group (Panels D and E). TNFα secretion 
reached statistical significance at T21 (p=0,02), while IL-12 is already 
significant at T3 (p=0,043). Such significance was maintained at 
subsequent time points (p=0,041, p=0,05). The data is confirmed in 
coexpression analysis (Panel F), at T5 and T21 cytokines percentage 
reached statistical significance (p=0,024, p=0,05). 
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Fig.11 Proinflammatory cytokine secretion. Percentages of pneumococcal-stimulated 
TNFα- (A), IL12- (B), and TNF-α/IL-12- (C) secreting dendritic cells (CD11c+), percentages 
of TNFα- (D), IL12- (E), and TNF-α/IL-12- (F) CD14+ cells are shown at baseline and in 
response to therapy in children with community-acquired pneumonia (CAP) treated with 
antibiotics plus pidotimod and in controls treated with antibiotics only. For each analysis, 
30,000 events were acquired and gated on CD11c and CD14 expression and side scatter 
properties. Mean values + SD and statistically significant differences are indicated. 
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1.1.4 Modulation of targets involved in antibacterial response 
Gene expression was evaluated by Real Time PCR array technology. 
Figure 12 summarizes gene expression related to the antibacterial 
response signaling pathway after pneumococcal polysaccharide 
stimulation. Expression of antimicrobial peptides reached a peak of 
expression at day 5 with a subsequent decrease at day 21. A similar trend 
was observed in both groups of patients, but the increases were more 
pronounced in the PDT-treated individuals. Amongst the genes that were 
significantly upregulated by pidotimod: Baculoviral IAP Repeat Containing 3 
(BIRC3) encodes a member of the IAP family of proteins that inhibit 
apoptosis by binding to tumor necrosis factor receptor-associated factors 
TRAF1 and TRAF2; Caspasi 1 (CASP1) encodes a protein which is a 
member of the cysteine-aspartic acid protease (caspase) family. Sequential 
activation of caspases plays a central role in the execution-phase of cell 
apoptosis; CD14 encodes a protein that is preferentially expressed on 
monocytes/macrophages; NLR family pyrin domain containing 1 (NLRP1) 
encodes a member of the Ced-4 family of apoptosis proteins. Ced-family 
members contain a caspase recruitment domain (CARD) and are known to 
be key mediators of programmed cell death. 
Likewise, an upregulation of inflammatory response genes was also 
observed in the PDT-treated group in comparison with the control group. 
The represented genes are those which are modulated following 
stimulation. Among them, CCL3, CXCL1 and CXCL2 are genes involved in 
synthesis of chemokines; IL1β, IL6, IL8 and IL18 encode for the 
inflammatory interleukin; NF-kB and NLRP3 that have a key role in 
regulating the inflammation.   
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Fig.12 Antibacterial response signaling pathway 
Antimicrobial peptides (Panel A) and genes involved in the inflammatory response (Panel B)  
at baseline as well as at days 3, 5 and 21 in children with community-acquired pneumonia 
(CAP) treated with antibiotics plus pidotimod and in controls treated with antibiotics only. 
Thus, the results represent the mean values of the different targets analyzed in the PDT 
versus Placebo subjects. Only values > 2-fold were considered significative. Standard 
deviations (SD) are not shown because the data were obtained by pool of cDNA sample. 
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1.2 LPS-stimulated immune response  
LPS stimulation has been used as positive control. Results on DC and 
monocyte activation, on proinflammatory cytokine secretion were similar to 
how obtained upon pneumococcal-specific stimulation. 
 
1.2.1 Dendritic cell activation and maturation 
Upon LPS stimulation, DCs undergo maturation and activation through 
upregulation of HLA DRII and costimulatory molecules CD80 and CD86. In 
particular, the differences reached statistical significance at each time point 
(T3: p=0,011; T5: p=0,013; and T21 p=0,015). No significative differences 
are observed in TNFα and IL12 production, even if in PDT treated group an 
increased secretion of both cytokines was reported at T3, T5 and T21 
(Figure 13).  
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Fig. 13 Effects of LPS on DCs. 
Percentage of CD80, CD86 and HLA DRII expression (A), and proinflammatory cytokines 
secretion (B). For each analysis, 30,000 events were acquired and gated on CD11c 
expression and side scatter properties. Mean values + SD and statistically significant 
differences are indicated. 
 
 
1.2.2 TLR expression and cytokine secretion in monocytes 
We observed monocyte activation upon LPS stimulation as well. TLR2 and 
TLR4 increased in PDT group at T3, T5 and T21 compared to the control 
group, in particular 21 days after the initiation of the therapy results showed 
statistical significance (p=0,03). In agreement with previous results, also 
proinflammatory cytokine secretion (TNFα and IL12) increase in PDT group 
at each time points but with no statistical significance (Figure 14). 
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Fig. 14 Effects of LPS on monocytes. 
Percentage of TLR2 and TLR4 expression on CD14+ cells (A), and  proinflammatory 
cytokines secretion (B). For each analysis, 30,000 events were acquired and gated on CD14 
expression and side scatter properties. Mean values + SEM and statistically significant 
differences are indicated. 
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2. ADULT PATIENTS 
 
2.1 Pneumococcal response 
The expression of surface molecules and cytokine secretion were assessed 
upon PBMC stimulation in vitro with pneumococcal polysaccharides.  
PBMCs were analysed at different time points (T0, T1, T3 and T5) in PDT 
group compared to controls. 
Results showed that PDT modified dendritic cells and monocytes functions. 
 
2.1.1 Dendritic cells activation 
The data regarding DCs maturation according to treatment arm are 
reported in Figure 15 were characterized by analyzing the expression of 
surface markers associated with cell activation and maturation, MHC class 
II molecules (HLA-DRII) and costimulatory molecules (CD80, CD86).  
Results indicate that HLA class II expressing DCs were increased, albeit 
not significantly, at day 5 in the pidotimod group, indicating that antigen 
presentation might be improved by pidotimod. The percentage of CD80- 
and CD86-expressing DC was increased as well at day 3 in the treated 
group compared to the control group; in this case, the differences were 
statistically significant (p<0.05). Because CD80 and CD86 are key proteins 
in initiating B-T lymphocytes collaboration and in the generation of 
antibodies, these results suggest that pidotimod has the ability to optimize 
this phase of the immune response. 
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Fig.15 Percentages of pneumococcal-stimulated positive dendritic cells. 
CD11c+ expressing HLA-DRII (A), CD80 (B), and CD86 (C). Molecules are shown at 
baseline and in response to therapy in adults with community-acquired pneumonia (CAP) 
treated with antibiotics plus pidotimod and in controls treated with antibiotics only. For each 
analysis, 30,000 events were acquired and gated on CD11c expression and side scatter 
properties. Mean values + SEM and statistically significant differences are indicated. 
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2.1.2 TLRs expression on monocyte surface 
Microbial infections stimulate innate immunity via binding of PAMPs they 
express to TLRs. Results showed that TLR2- and TLR4-expressing CD14+ 
cells (monocytes) were significantly increased in patients in whom 
pidotimod was added to the standard antibiotics therapy. 
Both TLR2 and TLR4 expression on monocytes was significantly higher in 
the PDT group compared with the untreated group 5 days after treatment 
initiation, with a significant p value (p=0,018 and p=0,028, respectively) 
(Figure 16).  
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Fig.16 Percentage of TLRs in monocytes. 
TLR2 (A) and TLR4 (B) expressing CD14+ monocytes in control and PDT patients analysed 
at baseline, 1, 3, and 5 days of therapy. For each analysis, 30,000 events were acquired 
and gated on CD14 expression and side scatter properties. Mean values + SEM and 
statistically significant differences are indicated. 
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2.1.3 Cytokines secretion by immunocompetent cells 
To evaluate whether pidotimod could modulate the production of cytokines 
from immune cells, TNFα- and IL12- producing monocytes and DCs were 
measured in pneumococcal-stimulated PBMCs. Results in Figure 17 
showed that, whereas no consistent effects of pidotimod on IL12-producing 
immune cells could be detected, TNF-α-producing monocytes and DCs 
were robustly reduced in pidotimod patients.  
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Fig.17 PDT effects in cytokines secretion. 
Percentage of TNFα- and IL12-secreting dendritic cells (A-B) and monocytes (C-D) in 
control and PDT patients analysed at baseline, 1, 3, and 5 days of therapy. Mean values, 
SEM, and p values are indicated. 
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2.1.4 Modulation of targets involved in antibacterial response 
The ability of pidotimod to stimulate antimicrobial and immunomodulatory 
peptides was evaluated in all the individuals enrolled in the study. Data 
obtained in unstimulated PBMCs 3 days after the initiation of therapy 
indicated that a number of genes that codify proteins endowed with 
antimicrobial properties were significantly upregulated in the pidotimod + 
antibiotic compared to antibiotics alone group (Figure 18). Only those 
targets showing at least a 2-fold difference in the two groups were 
considered as those to be significantly modulated. Amongst the genes that 
were significantly upregulated by pidotimod: Bactericidal/Permeability-
Increasing Protein (BPI), cathepsin G (CTSG) and myeloperoxidase (MPO) 
encode molecules that are associated with the antimicrobial functions of 
human neutrophil granules; Cathelicidin Antimicrobial Peptide (CAMP), C 
reactive protein (CRP), and lipocalin 2 (LCN2) encode proteins that elicit 
and amplify innate and acquired immune responses; lactoferrin (LTF) binds 
to the bacterial surface and has direct antimicrobial functions; and 
Secretory Leukocyte Peptidase Inhibitor (Slpi) produces a protein which 
protects epithelial tissues from attack by endogenous proteolytic enzymes. 
The effects of pidotimod on inflammatory responses were analyzed as well 
in unstimulated PBMCs. Results shown in Figure 19, indicated PDT effects 
on unstimulated PBMC. 3 days after initiation of therapy (Panel A), genes 
responsible for the generation of cytokines (CCL and CXL) as well as those 
for the inflammatory cytokines IL1b and TNFα were down regulated. 
Contrariwise, type 1 IFNs, IL-6 and IL-12 were upregulated in the pidotimod 
+ antibiotic compared to the antibiotics alone group. Notably, at day 5 
(Panel B) the picture was different.  The addition of pidotimod to the 
standard therapy resulted in a massive increase in mRNA for both CCL and 
CXL chemokines, whereas mRNA for type 1 IFN, TNFa, IL-6, IL-12 was 
greatly reduced as compared to the values observed on day 3. 
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Fig.18 Antimicrobial peptides expression. 
Unstimulated PBMCs 3 days after initiation of the therapy; CAP patients treated with 
antibiotics plus pidotimod (PDT) vs controls treated with antibiotics only. Experiments were 
run on samples from all the subjects included in the study, pooled into two groups: PDT and 
controls. Thus, the results represent the mean values of the different targets analyzed in the 
PDT vs placebo subjects. Only increases > 2-fold were considered significative. 
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Fig.19 Inflammatory response markers expression. 
Unstimulated PBMCs 3 (Panel A) and 5 days (Panel B) after initiation of the therapy; CAP 
patients treated with antibiotics plus pidotimod (PDT) VS controls treated with antibiotics 
only. Experiments were run on samples from all the subjects included in the study pooled 
into two groups: PDT and Placebo. Thus, the results represent the mean values of the 
different targets analyzed in the PDT versus Placebo subjects. Only increases > 2-fold were 
considered significative. 
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2.2 LPS response 
Also in adult patients LPS stimulation led to the similar results (Figure 20). 
DRII expression showed no difference between two groups (Panel A), while 
CD80 and CD86 increase their expression in the treated group than control 
(Panel B and C), in particular at T3, were CD80 reach statistical 
significance with p value of 0,01. It is possible observe the same trend also 
in cytokine secretion (panel D and E), although it never reached statistical 
significance, where the secretion of both IL12 and TNFα was increased in 
treated group. On monocytes, we didn’t observe difference with 
pneumococcal stimulation. TLRs expression increased in PDT group 
compared to placebo, in particular at T3, while in cytokines secretion there 
was no difference between two groups at different time points (data not 
shown).  
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Fig.20 DCs activation.  
Percentages of LPS-stimulated positive dendritic cells (CD11c+) expressing HLA-DRII (A), 
CD86 (B), and CD80 (C), cytokines secretion IL12 (D), and TNFα (E). Molecules are shown 
at baseline and in response to therapy in adults with community-acquired pneumonia (CAP) 
treated with antibiotics plus pidotimod and in controls treated with antibiotics only. For each 
analysis, 30,000 events were acquired and gated on CD11c expression and side scatter 
properties. Mean values + SEM and statistically significant differences are indicated. 
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Immunostimulators are known and studied since 90s. In particular, 
pidotimod was longed studied. Several in vitro studies showed its effects on 
Dendritic cells maturation and activation, and on differentiation of CD4+ 
naïve T cells towards a TH1-polarizing phenotype [61,76]. PDT promotes 
upregulation of TLR2 and a significant increase in NF-kB protein 
expression and NF-kB nuclear translocation [65]. In vivo studies confirmed 
previous results, further it was demonstrated that PDT enhances NK cell 
function and promotes phagocytosis [77]. In Down Syndrome patients, PDT 
administration in conjunction with flu vaccine, induces a potentiation of 
immune responses and, in particular, in innate immunity [2].  
Its effects on both, innate and adaptive immunity, have made PDT a good 
candidate for treatment of several diseases. In this study we analysed PDT 
effects for the treatment of comunity-acquired pneumonia. Promising 
results were obtained. Our data indicate that PDT administration in addition 
to standard antibiotic therapy in children with CAP may significantly 
increase natural immune system responses to an infectious stimulus via a 
direct influence on DCs maturation and function, TLR2 expression in 
monocytes, antimicrobial peptide secretion and upregulation of genes 
involved in inflammatory response. The positive effect was reported after 
only  few days of PDT administration and remained evident for several days 
after PDT treatment ended. In agreement with previous data, results 
obtained in adults confirm that Pidotimod significantly increases the 
percentage of TLR2 and TLR4-expressing CD14+ cells and the production 
of chemokines as well as the expression of CD80 and CD86, crucial 
costimulatory receptor involved in the collaboration between T and B 
lymphocytes, and the modulation of the generation of cytokines by immune 
cells. 
At steady state, DCs are described as immature, a phenotype 
characterized by low surface expression of MHC class II molecules and co-
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stimulatory molecules such as CD80 and CD86. In response to activation 
(e.g. infections), DCs undergo a program of maturation that leads to the 
acquisition of a number of fundamental properties including antigen 
processing and presentation, migration and T cell co-stimulation. In this 
context, upregulation of co-stimulatory molecules and HLA-DRII antigens is 
evidenced together with a significant production of pro-inflammatory 
cytokines, such as IL-12 and TNF-α, which play an important role in the 
polarization of T helper cell subsets toward a Th1 profile during priming by 
DCs [78]. TLR2 plays a major role in promoting protective immunity against 
respiratory pathogens [79], and its upregulation could reduce susceptibility 
to further respiratory infections. In PDT-treated children, the increased 
expression of antimicrobial peptides and genes involved in cell chemotaxis, 
the upregulation of the inflammatory response and increased apoptosis 
[80,81], suggest that PDT administration might significantly increase the 
activity of the immune system for a long period of time, thus reducing the 
risk of early recurrences during CAP in children. 
The observations that TLR2 and TLR4 are up regulated by Pidotimod in 
CAP patients is important as these receptors recognise molecules that are 
part of bacterial cell wall and are produced during bacterial replication. 
TLRs biding to PAMPS initiates innate immune responses that are 
mediated by cytokines and stimulates antimicrobial peptides production 
[39,40].  
In adults, Pidotimod is associated with a reduced synthesis of TNFa, a 
proinflammatory cytokine whose excessive production is known as a 
negative prognostic factor in CAP. These are preliminary data that need to 
be confirmed  in a larger group of patients, but, taken together, combined 
results of these two cohorts of patients undeline that Pidotimod is endowed 
with immunomodulatory abilities. 
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 From a clinical point of view no significant differences between the two 
groups in terms of time to clinical stability and symptoms resolution were 
recorded. In conclusion, results herein support the proposal to verify the 
possible clinical benefits of Pidotimod-associated immune modulation in 
larger populations, possibly including complicated CAP cases. 
Furthermore, its beneficial effects on both innate and adaptive immunity,  
make it an excellent candidate as adjuvant in the vaccines.  So it would be 
interesting, as future perspectives,  to analyse its efficacy in vaccine 
formulation.
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